{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:50:32Z","timestamp":1791953432569,"version":"4.3.4"},"reference-count":9,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJTLD Open"],"accepted":{"date-parts":[[2026,6,24]]},"published-print":{"date-parts":[[2026,10]]},"DOI":"10.5588\/ijtldopen.26.0341","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:30:47Z","timestamp":1791952247000},"page":"670-673","source":"Crossref","is-referenced-by-count":0,"title":["Pembrolizumab and reactivation of TB: is there a link?"],"prefix":"10.5588","volume":"3","author":[{"given":"N.","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"SONI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.N.","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Singhania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101321304086000_3.10.670.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01121-x"},{"key":"2026101321304086000_3.10.670.2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2021-217260"},{"issue":"3","key":"2026101321304086000_3.10.670.3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.resinv.2024.02.002","article-title":"Cancer immunotherapy with immune checkpoint inhibitors and infections: a particular focus on mycobacterial infections","volume":"62","author":"Fujita","year":"2024","journal-title":"Respir Investig"},{"key":"2026101321304086000_3.10.670.4","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003304"},{"issue":"7","key":"2026101321304086000_3.10.670.5","first-page":"e2105","article-title":"Immune checkpoint inhibitors and tuberculosis: a review","volume":"73","author":"Ratner","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2026101321304086000_3.10.670.6","first-page":"123","article-title":"Risk of tuberculosis reactivation in patients treated with anti-PD-1\/PD-L1 agents","volume":"19","author":"Cantini","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2026101321304086000_3.10.670.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.015"},{"key":"2026101321304086000_3.10.670.8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0717-7"},{"key":"2026101321304086000_3.10.670.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2017.12.003"}],"container-title":["IJTLD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.5588\/ijtldopen.26.0341","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:30:52Z","timestamp":1791952252000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.theunion.org\/lookup\/doi\/10.5588\/ijtldopen.26.0341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":9,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.5588\/ijtldopen.26.0341"],"URL":"https:\/\/doi.org\/10.5588\/ijtldopen.26.0341","relation":{},"ISSN":["3005-7590"],"issn-type":[{"value":"3005-7590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}